These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 29702540)

  • 1. Safety of Dexamethasone for Nausea and Vomiting Prophylaxis in Children Receiving Hematopoietic Stem Cell Transplantation.
    Paw Cho Sing E; Schechter T; Ali M; Sung L; Dupuis LL
    J Pediatr Hematol Oncol; 2018 Jul; 40(5):e278-e282. PubMed ID: 29702540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Palonosetron (Aloxi) and dexamethasone for the prevention of acute and delayed nausea and vomiting in patients receiving multiple-day chemotherapy.
    Musso M; Scalone R; Bonanno V; Crescimanno A; Polizzi V; Porretto F; Bianchini C; Perrone T
    Support Care Cancer; 2009 Feb; 17(2):205-9. PubMed ID: 18839220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of nabilone for acute chemotherapy-induced vomiting prophylaxis in pediatric patients: A multicenter, retrospective review.
    Polito S; MacDonald T; Romanick M; Jupp J; Wiernikowski J; Vennettilli A; Khanna M; Patel P; Ning W; Sung L; Dupuis LL
    Pediatr Blood Cancer; 2018 Dec; 65(12):e27374. PubMed ID: 30051617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative Quantification of Chemotherapy-Induced Nausea and Emesis between the Common Terminology Criteria for Adverse Events and the Multinational Association of Supportive Care in Cancer Antiemesis Tool.
    Uchida M; Nakamura T; Shima T; Yoshimoto G; Kato K; Hosohata K; Miyamoto T; Akashi K
    Biol Pharm Bull; 2018; 41(11):1667-1671. PubMed ID: 30381666
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemotherapy-Induced Nausea and Vomiting Prophylaxis: Practice Within the Children's Oncology Group.
    Patel P; Robinson PD; Orsey A; Freedman JL; Langevin AM; Woods D; Sung L; Dupuis LL
    Pediatr Blood Cancer; 2016 May; 63(5):887-92. PubMed ID: 26864262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The burden of chemotherapy-induced nausea and vomiting in children receiving hematopoietic stem cell transplantation conditioning: a prospective study.
    Flank J; Sparavalo J; Vol H; Hagen L; Stuhler R; Chong D; Courtney S; Doyle JJ; Gassas A; Schechter T; Dupuis LL
    Bone Marrow Transplant; 2017 Sep; 52(9):1294-1299. PubMed ID: 28581463
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of an Oral Fixed Combination of Netupitant and Palonosetron (NEPA): Pooled Data From the Phase II/III Clinical Program.
    Aapro M; Hesketh PJ; Jordan K; Gralla RJ; Rossi G; Rizzi G; Palmas M
    Oncologist; 2016 Apr; 21(4):494-502. PubMed ID: 27000465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Palonosetron and dexamethasone for prevention of nausea and vomiting in patients receiving high-dose chemotherapy with auto-SCT.
    Musso M; Scalone R; Crescimanno A; Bonanno V; Polizzi V; Porretto F; Bianchini C; Perrone T
    Bone Marrow Transplant; 2010 Jan; 45(1):123-7. PubMed ID: 19483762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of 5-HT(3) RA selection within triple antiemetic regimens on uncontrolled highly emetogenic chemotherapy-induced nausea/vomiting.
    Schwartzberg L; Jackson J; Jain G; Balu S; Buchner D
    Expert Rev Pharmacoecon Outcomes Res; 2011 Aug; 11(4):481-8. PubMed ID: 21711119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined use of multiday palonosetron with aprepitant and low-dose dexamethasone in prevention of nausea and emesis among patients with multiple myeloma and lymphoma undergoing autologous hematopoietic stem cell transplant: A pilot study.
    Deauna-Limayo D; Aljitawi OS; Ganguly S; Abhyankar S; Wick JA; McGuirk JP
    J Oncol Pharm Pract; 2014 Aug; 20(4):263-9. PubMed ID: 24005093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Poor chemotherapy-induced nausea and vomiting control in children receiving intermediate or high dose methotrexate.
    Vol H; Flank J; Lavoratore SR; Nathan PC; Taylor T; Zelunka E; Maloney AM; Lee Dupuis L
    Support Care Cancer; 2016 Mar; 24(3):1365-71. PubMed ID: 26335406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of olanzapine combined with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy in gynecological cancer: KCOG-G1301 phase II trial.
    Abe M; Hirashima Y; Kasamatsu Y; Kado N; Komeda S; Kuji S; Tanaka A; Takahashi N; Takekuma M; Hihara H; Ichikawa Y; Itonaga Y; Hirakawa T; Nasu K; Miyagi K; Murakami J; Ito K
    Support Care Cancer; 2016 Feb; 24(2):675-682. PubMed ID: 26130365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aprepitant plus palonosetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy.
    Gao HF; Liang Y; Zhou NN; Zhang DS; Wu HY
    Intern Med J; 2013 Jan; 43(1):73-6. PubMed ID: 22141732
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial.
    Saito M; Aogi K; Sekine I; Yoshizawa H; Yanagita Y; Sakai H; Inoue K; Kitagawa C; Ogura T; Mitsuhashi S
    Lancet Oncol; 2009 Feb; 10(2):115-24. PubMed ID: 19135415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: A systematic review and meta-analysis.
    Yoodee J; Permsuwan U; Nimworapan M
    Crit Rev Oncol Hematol; 2017 Apr; 112():113-125. PubMed ID: 28325253
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aprepitant, granisetron, and dexamethasone for prevention of chemotherapy-induced nausea and vomiting after high-dose melphalan in autologous transplantation for multiple myeloma: results of a randomized, placebo-controlled phase III trial.
    Schmitt T; Goldschmidt H; Neben K; Freiberger A; Hüsing J; Gronkowski M; Thalheimer M; Pelzl le H; Mikus G; Burhenne J; Ho AD; Egerer G
    J Clin Oncol; 2014 Oct; 32(30):3413-20. PubMed ID: 25225424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Palonosetron is nonsuperior to ondansetron in acute phase but provides superior antiemetic control in delayed phase for pediatric patients administered highly emetogenic chemotherapy.
    Tan J; Wang S; Liang X; Li CC; Zhang J; Zhao Z; Kong XR; Deng X; Peng L; Yang C
    Pediatr Blood Cancer; 2018 Feb; 65(2):. PubMed ID: 28941006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk Model-Guided Antiemetic Prophylaxis vs Physician's Choice in Patients Receiving Chemotherapy for Early-Stage Breast Cancer: A Randomized Clinical Trial.
    Clemons M; Bouganim N; Smith S; Mazzarello S; Vandermeer L; Segal R; Dent S; Gertler S; Song X; Wheatley-Price P; Dranitsaris G
    JAMA Oncol; 2016 Feb; 2(2):225-31. PubMed ID: 26562292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting (CINV): a retrospective study.
    Chiu L; Chiu N; Chow R; Zhang L; Pasetka M; Stinson J; Lechner B; Pulenzas N; Verma S; Chow E; DeAngelis C
    Ann Palliat Med; 2016 Jul; 5(3):172-8. PubMed ID: 27199269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prophylaxis of acute chemotherapy-induced nausea and vomiting in children with cancer: what is the evidence?
    Antonarakis ES; Evans JL; Heard GF; Noonan LM; Pizer BL; Hain RD
    Pediatr Blood Cancer; 2004 Nov; 43(6):651-8. PubMed ID: 15390297
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.